MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

First Posted Date
2021-01-22
Last Posted Date
2021-06-04
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
60
Registration Number
NCT04717531
Locations
🇨🇳

the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Myeloid Leukemia
Monocytic Leukemia
Interventions
Drug: Daratumumab/rHuPH20
Drug: FT538
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2021-01-19
Last Posted Date
2024-10-24
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
9
Registration Number
NCT04714372
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Phase 1
Recruiting
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Biological: anti-BCMA CAR-T
Drug: Cyclophosphamid
Drug: Fludarabine
First Posted Date
2021-01-13
Last Posted Date
2023-02-06
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
25
Registration Number
NCT04706936
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Phase 1
Recruiting
Conditions
Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Decitabine-primed Tandem CD19/CD20 CAR T Cells
Interventions
Biological: Decitabine-primed Tandem CAR19/20 engineered T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2021-01-06
Last Posted Date
2024-02-07
Lead Sponsor
Han weidong
Target Recruit Count
33
Registration Number
NCT04697940
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1
Recruiting
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Genetic: ALLO-316
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2021-01-06
Last Posted Date
2024-11-01
Lead Sponsor
Allogene Therapeutics
Target Recruit Count
120
Registration Number
NCT04696731
Locations
🇺🇸

UCSF Medical Center, San Francisco, California, United States

🇺🇸

Yale School of Medicine, New Haven, Connecticut, United States

🇺🇸

Georgetown University Hospital, Washington, District of Columbia, United States

and more 7 locations

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

First Posted Date
2020-12-29
Last Posted Date
2023-02-21
Lead Sponsor
Yi Luo
Target Recruit Count
46
Registration Number
NCT04688021
Locations
🇨🇳

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

IS-free Treg HaploHCT

Phase 1
Recruiting
Conditions
Stem Cell Transplant Complications
Graft Vs Host Disease
Myeloid Leukemia, Acute
Myeloid Leukemia in Relapse (Disorder)
Myelodysplastic Syndromes
Interventions
Radiation: Radiation
Drug: Fludarabine
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Mesna
Biological: Treg-enriched donor cell
Biological: Unmodified donor T Cell
Procedure: CD34+ Haplo Peripheral Blood Stem Cell
First Posted Date
2020-12-22
Last Posted Date
2024-12-04
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT04678401
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase 2
Recruiting
Conditions
Chronic Lymphocytic Leukemia
Richter Syndrome
Interventions
Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Hydroxydaunomycin
First Posted Date
2020-12-22
Last Posted Date
2024-10-31
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
20
Registration Number
NCT04679012
Locations
🇺🇸

Weill Cornell Medicine, New York, New York, United States

🇺🇸

Mount Sinai- Icahn School of Medicine, New York, New York, United States

🇺🇸

Columbia University Medical Center, New York, New York, United States

and more 1 locations

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Phase 2
Conditions
Triple Negative Breast Cancer
Interventions
Biological: Camrelizumab
Drug: Nab paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide
First Posted Date
2020-12-21
Last Posted Date
2020-12-21
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
20
Registration Number
NCT04676997
Locations
🇨🇳

Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University Recruiting, Jinan, Shandong, China

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Drug: CC-95266
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
First Posted Date
2020-12-19
Last Posted Date
2024-01-26
Lead Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Target Recruit Count
180
Registration Number
NCT04674813
Locations
🇺🇸

Local Institution - 008, Baltimore, Maryland, United States

🇺🇸

Local Institution - 009, Duarte, California, United States

🇺🇸

Local Institution - 011, New York, New York, United States

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy